Skip to main content

Small-cell lung cancer

Latest articles

25-06-2019 | Oncology | News | Article

Pembrolizumab approved in USA for metastatic SCLC

Click through for the details of this FDA decision

07-06-2019 | Oncology | News | Article

Lurbinectedin shows potential for second-line SCLC treatment

Lurbinectedin monotherapy is active in the second-line treatment of both platinum-sensitive and -resistant small-cell lung cancer, according to phase II results presented at the 2019 ASCO Annual Meeting.

24-05-2019 | Oncology | News | Article

Twice-daily radiotherapy may increase brain metastasis risk in SCLC

Marginal survival gains among patients with small-cell lung cancer who receive twice- versus once-daily thoracic radiotherapy plus prophylactic cranial irradiation occur at the cost of an increased risk for brain metastases, research shows.

17-05-2019 | Oncology | News | Article

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

16-04-2019 | Oncology | News | Article

CheckMate 451: Maintenance immunotherapy fails to improve SCLC survival

Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.

02-04-2019 | Oncology | News | Article

Pembrolizumab supported for third- or later-line extensive-stage SCLC

Single-agent pembrolizumab could be a promising option for extensive-stage small-cell lung cancer patients who have received at least two prior lines of therapy, suggests a pooled analysis of data from the multicohort KEYNOTE-028 and -158 trials.

25-03-2019 | Oncology | Main feed | News

FDA approves atezolizumab for extensive-stage SCLC

Click here to read more on this announcement

21-12-2018 | Non-small-cell lung cancer | News | Article

Clinical course of EGFR-mutant NSCLC transforming to SCLC documented

Epidermal growth factor receptor-mutant non-small-cell lung cancer that transforms to small-cell lung cancer is characterized by a high rate of TP53 mutation and a lack of response to immunotherapy, among other features, show researchers.

14-12-2018 | Small-cell lung cancer | News | Article

Veliparib shows efficacy in some patients with extensive-stage SCLC

Some patients with extensive-stage small-cell lung cancer may benefit from the addition of the poly(ADP ribose) polymerase inhibitor veliparib to standard chemotherapy, but further confirmation of its efficacy is needed, say researchers.

27-09-2018 | Oncology | News | Article

Atezolizumab–chemotherapy combination boosts extensive-stage SCLC survival

The addition of atezolizumab to chemotherapy has significantly improved both the overall survival and progression-free survival of treatment naïve-patients with extensive-stage small-cell lung cancer, results from the IMpower133 trial indicate.

22-08-2018 | Oncology | News | Article

FDA announces approvals for metastatic SCLC, unresectable HCC

Click through to see which drugs are now available for these patient populations

02-02-2018 | Oncology | News | Article

In other news

In this month’s roundup we cover pharmaceutical smoking-cessation aids, the effects of TP53 mutations in children with acute lymphoblastic leukemia, and the barriers to receiving standard of care treatment in US patients with limited-stage small-cell lung cancer.

27-09-2017 | Oncology | News | Article

Preliminary lurbinectedin results ‘remarkable’ for relapsed SCLC

Lurbinectedin has potential for the treatment of patients with relapsed small-cell lung cancer as a single agent or in combination with another chemotherapy drug, suggests research reported at the ESMO 2017 Congress in Madrid, Spain.

05-09-2017 | Oncology | News | Article

KEYNOTE-028 results point to pembrolizumab efficacy in SCLC, nasopharyngeal cancer

Findings from the multicohort, phase Ib KEYNOTE-028 trial indicate that pembrolizumab elicits durable responses and is well tolerated in patients with extensive-stage small-cell lung cancer and those with recurrent or metastatic nasopharyngeal carcinoma.

14-07-2017 | Oncology | News | Article

In other news

Here we report on the optimal radiotherapy regimen for patients with small-cell lung cancer, as well as the outcomes of adding evofosfamide to doxorubicin in the first-line soft tissue sarcoma setting and continuing nivolumab after progression in advanced melanoma.

21-12-2016 | Small-cell lung cancer | News | Article

Drug targeting DLL3 shows ‘encouraging’ results in small-cell lung cancer

Rovalpituzumab tesirine, a first-in-class antibody–drug conjugate directed against delta-like protein 3, shows promising antitumor activity in patients with recurrent small-cell lung cancer, US researchers report.

20-10-2015 | Lung cancer | News | Article

Early trial results in lung cancer

Results from early phase trials investigating different therapeutic agents in lung cancer patients were presented during the third Presidential Session at the European Cancer Congress in Vienna, Austria. Here we summarise two studies reported at the session.

Image Credits